Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-01-25
2011-01-25
Yu, Misook (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S130100
Reexamination Certificate
active
07875704
ABSTRACT:
The present invention provides novel monoclonal antibodies directed to PlGF and fragments and derivatives thereof, more particularly to humanized antibodies and fragments thereof for use in the treatment and/or prevention of pathological angiogenesis.
REFERENCES:
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5851999 (1998-12-01), Ullrich et al.
patent: 5919899 (1999-07-01), Persico et al.
patent: 2003/0180286 (2003-09-01), Carmeliet et al.
patent: 1297016 (2006-03-01), None
patent: 1869085 (2007-12-01), None
patent: WO 84/03564 (1984-09-01), None
patent: WO 99/24056 (1999-05-01), None
patent: WO 99/60846 (1999-12-01), None
patent: WO 01/85796 (2001-11-01), None
patent: WO 2006/099698 (2006-09-01), None
Rudikoff et al. Proc Natl Acad Sci USA 1982 vol. 79 p. 1979.
MacCallum et al. J. Mol. Biol. (1996) 262, 732-745.
Pascalis et al. The Journal of Immunology (2002) 169, 3076-3084.
Casset et al. (2003) BBRC 307, 198-205.
Vajdos et al. Journal of Molecular Biology. (2002) 320, 415-428.
Chen et al. J. Mol. Bio. (1999) 293, 865-881.
Wu et al. J. Mol. Biol. (1999) 294, 151-162.
Holm et al. Molecular Immunology, (2007) 44, 1075-1084.
Mueller et al. PNAS vol. 89 pp. 11832-11836, Dec. 1992.
Attwood (Science 290: 471-473, 2000).
Skolnick et al. (Trends in Biotech. 18: 34-39, 2000).
Office Action for European Patent Application No. 06 721 544.2, dated Apr. 15, 2009.
English Language Translation of the Office Action issued in connection with Israeli Patent Application No. 185754, dated Jan. 24, 2010.
Ahmed et al., “Regulation of Placental Vascular Endothelial Growth Factor (VEGF) and Placenta Growth Factor (PlGF) and Soluble Flt-1 by Oxygen—A Review,”Placenta21(Suppl. A):S16-S24, 2000.
Barillari et al., “The Basic Residues of Placenta Growth Factor Type 2 Retrieve Sequestered Angiogenic Factors into a Soluble Form,”Am. J. Pathol.152:1161-1166, 1998.
Bernatchez et al., “Vascular Endothelial Growth Factor Effect on Endothelial Cell Proliferation, Migration, and Platelet-Activating Factor Synthesis Is Flk-1-Dependent,”J. Biol. Chem.274:31047-31054, 1999.
Bicknell et al., “Introduction,” inTumor Angiogenesis, Ed. Bicknell et al., Oxford University Press Inc., New York, NY, pp. 1-3, 1997.
Bottomley et al., “Placenta Growth Factor (PlGF) Induced Vascular Endothelial Growth Factor (VEGF) Secretion from Mononuclear Cells and Is Co-Expressed with VEGF in Synovial Fluid,”Clin. Exp. Immunol. 119:182-188, 2000.
Brenchley, “Angiogenesis in Inflammatory Joint Disease: A Target for Therapeutic Intervention,”Clin. Exp. Immunol. 121:426-429, 2000.
Carmeliet, “Molecular Mechanisms of Normal and Pathologic Angiogenesis: Insights and Therapeutic Concepts from Transgenic Mice,”J. Vasc. Res. 37(Suppl. 1):79, 2000. Abstract No. 46.
Carmeliet, “Mechanisms of Angiogenesis and Arteriogenesis,”Nature Medicine6:389-395, 2000.
Christinger et al., “The Crystal Structure of Placental Growth Factor in Complex with Domain 2 of Vascular Endothelial Growth Factor Receptor-1,”J. Biol. Chem.279:10382-10388, 2004.
Colucciello, “Proliferative Diabetic Retinopathy,”Postgraduate Medicine Online, vol. 116, No. 1, 2004 (http://www.postgradmed.com.issues/2004/07—04/colucciello.htm).
Declerck et al., “Generation of Monoclonal Antibodies Against Autologous Proteins in Gene-Inactivated Mice,”J. Biol. Chem.270:8397-8400, 1995.
Donnini et al., “Expression and Localization of Placenta Growth Factor and P1GF Receptors in Human Meningiomas,”J. Pathol. 189:66-71, 1999.
Fan et al., “In Vivo Models of Angiogenesis,” inTumor Angiogenesis, Ed. Bicknell et al., Oxford University Press Inc., New York, NY, pp. 5-18, 1997.
Fidler et al., “Biology of Cancer: Angiogenesis,” in Cancer: Principles & Practice of Oncology, 6th Edition, Ed. DeVita Jr. et al., Lippincott, Williams & Wilkins, Philadelphia, PA, pp. 137-147, 2001.
Fischer et al., “Anti-PIGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors Without Affecting Healthy Vessels,”Cell131:463-475, 2007.
Folkman, “Clinical Applications of Research on Angiogenesis,”N. Eng. J. Med.333:1757-1763, 1995.
Griffioen et al., “Angiogenesis: Potentials for Pharmacologic Intervention in the Treatment of Cancer, Cardiovascular Diseases, and Chronic Inflammation,”Pharmacol. Reviews52:237-268, 2000.
Guidi et al., “Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) and Its Receptors in Endometrial Carcinoma,”Cancer78:454-460, 1996.
Gura et al., Systems for Identifying New Drugs Are Often Faulty,Science278:1041-1042, 1997.
Hansma et al., “Recombinant Human Endostatin Administered as a 28-Day Continuous Intravenous Infusion, Followed by Daily Subcutaneous Injections: A Phase I and Pharmacokinetic Study in Patients with Advanced Cancer,”Ann. Oncol. 16:1695-1701, 2005.
Hazelton et al., “Vascular Endothelial Growth Factor in Ovarian Cancer,”Current Oncol. Reports1:59-63, 1999.
Inoue et al., “Mechanism of Mustard Oil-Induced Skin Inflammation in Mice,”Eur. J. Pharmacol.333:231-240, 1997.
Jain et al., “AlphaPIGF: A New Kid on the Antiangiogenesis Block,”Cell131:443-445, 2007.
Johnstone et al.,Immunochemistry in Practice, Blackwell Scientific Publications, Oxford, p. 30, 1987.
Kanno et al., “Roles of Two VEGF Receptors, Flt-1 and KDR, in the Signal Transduction of VEGF Effects in Human Vascular Endothelial Cells,”Oncogene19:2138-2146, 2000.
Katoh et al., “Expression of Vascular Endothelial Growth Factor (VEGF) in Human Thyroid Neoplasms,”Human Pathol.30:891-897, 1999.
Köhler et al., “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity,”Nature256:495-497, 1975.
Luttun et al., “Genetic Dissection of Tumor Angiogenesis: Are P1GF and VEGFR-1 Novel Anti-Cancer Targets?”Biochim. Biophys. Acta1654:79-94, 2004.
Maglione et al., “Isolation of a Human Placenta cDNA Coding for a Protein Related to the Vascular Permeability Factor,”Proc. Natl. Acad. Sci. U.S.A.88:9267-9271, 1991.
Maglione et al., “Two Alternative mRNA Coding for the Angiogenic Factor, Placenta Growth Factor (PIGF), Are Transcribed from a Single Gene of Chromosome 14,”Oncogene8:925-931, 1993.
Maragoudakis, “Introductory Comments,” inAdvances in Experimental Medicineand Biology, vol. 476:Angiogenesis from the Molecular to Integrative Pharmacology, Ed. Maragoudakis, Kluwer Academic/Plenum Publishers, Boston, MA, pp. 1-4, 2000.
Migdal et al., “Neurophilin-1 Is a Placenta Growth Factor-2 Receptor,”J. Biol. Chem. 273:22272-22278, 1998.
Miller, “Issues and Challenges for Antiangiogenic Therapies,”Breast Cancer Res. Treat.75(Suppl. 1):S45-S50, 2002.
MSNBC News Services, “Mixed Results on New Cancer Drug,” Nov. 9, 2000.
Nicol et al., “Vascular Endothelial Growth Factor Expression Is Increased in Renal Cell Carcinoma,”J. Urology157:1482-1486, 1997.
Nomura et al., “Placenta Growth Factor (PIGF) mRNA Expression in Brain Tumors,”J. Neuro-Oncol.40:123-130, 1998.
Oliver et al., “Suppression of Collagen-Induced Arthritis by an Angiogenesis Inhibitor, AGM-1470, in Combination with Cyclosporin: Reduction of Vascular Endothelial Growth Factor (VEGF),”Cell. Immunol.166:196-206, 1995.
Paleolog et al., “Angiogenesis in Arthritis: Role in Disease Pathogenesis and as a Potential Therapeutic Target,”Angiogenesis2:295-307, 1999.
Paques et al., “Growth Factors and Diabetic Retinopathy,”Diabetes Metabol.23:125-130, 1997.
Park et al., “Potentiation of Vascular Endothelial Growth Factor Bioactivity, In Vitro and In Vivo, and High Affinity Binding to Flt-1 But Not to Flk-1/KDR,”J. Biol. Chem.269:25646-25654, 1994.
Parry et al., “Bioactivity of Anti-Angiogenic Ribozymes Targeti
Carmeliet Peter
Collen Desire
Stassen Jean-Marie
Clark & Elbing LLP
Life Sciences Research Partners VZW
Natarajan Meera
Thrombogenics N.V.
Vlaams Interuniversitair Instituut voor Biotechnologie VZW
LandOfFree
Anti-PLGF antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-PLGF antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-PLGF antibody will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2734569